ALIMTA® , pemetrexed for injection, is an antifolate antineoplastic agent that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. Pemetrexed disodium heptahydrate has the chemical name L-Glutamic acid,
]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt, heptahydrate.
Mesothelioma: ALIMTA in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.
Non-Small Cell Lung Cancer: ALIMTA as a single-agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after prior chemotherapy.
The effectiveness of ALIMTA in second-line NSCLC was based on the surrogate endpoint, response rate. There are no controlled trials demonstrating a clinical benefit, such as a favorable survival effect or improvement of disease-related symptoms.
Media Articles Related to Alimta (Pemetrexed)
Scottish medicines consortium accepts the use of Alimta (pemetrexed) for maintenance treatment of non-small cell lung cancer
Source: Lung Cancer News From Medical News Today [2014.12.11]
On 8th December 2014, the Scottish Medicines Consortium accepted for use within NHS Scotland Alimta (pemetrexed) monotherapy for the maintenance treatment of locally advanced or metastatic...
Lung Cancer: Expanded Alimta Label
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has expanded the indication for the cancer drug pemetrexed injection to act as a maintenance therapy with cisplatin for nonsquamous non-small cell lung cancer.
Published Studies Related to Alimta (Pemetrexed)
Pemetrexed in combination with cisplatin versus cisplatin monotherapy in East
Asian patients with recurrent or metastatic head and neck cancer: Results of an
exploratory subgroup analysis of a phase III trial. 
trial was conducted to assess efficacy and safety trends based on ethnicity... CONCLUSION: Consistent with findings in the global population,
Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients
with recurrent or metastatic head and neck cancer: final results of a randomized,
double-blind, placebo-controlled, phase 3 study. 
pemetrexed-cisplatin for SCCHN... CONCLUSIONS: Pemetrexed-cisplatin compared with placebo-cisplatin did not
Quality of life in patients with advanced non-small-cell lung cancer given
maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from
a randomised, double-blind, phase 3 study. 
palliation, and tolerability are presented here... INTERPRETATION: Quality of life during maintenance therapy with pemetrexed is
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or
placebo in chemonaive patients with advanced non-small cell lung cancer. 
non-small cell lung cancer (NSCLC)... CONCLUSIONS: Enzastaurin and cisplatin-pemetrexed is tolerable with preliminary
Efficacy and safety of pemetrexed maintenance therapy versus best supportive care
in patients from East Asia with advanced, nonsquamous non-small cell lung cancer:
an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial. 
non-East Asian patients treated with pemetrexed or placebo... CONCLUSION: The results of this subgroup analysis support pemetrexed as
Clinical Trials Related to Alimta (Pemetrexed)
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients [Active, not recruiting]
Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop
them from dividing, or stop the growth of the blood supply that cancers need to grow and
spread. Clinical research has shown that drugs that inhibit vascular endothelial growth
factor receptor (VEGFR) or epidermal growth factor receptor (EGFR) signalling can increase
overall survival in patients with advanced non-small cell lung cancer (NSCLC). Preclinical
studies have shown that vandetanib (ZD6474) is an inhibitor of both VEGFR and EGFR
signalling. Giving vandetanib may therefore inhibit the growth of cancer cells by blocking
their blood supply and by stopping them from dividing. This lung cancer study is to
investigate if adding vandetanib to Alimta (pemetrexed) is more effective than Alimta
Study of AlimtaŽ (Pemetrexed) Plus VELCADEŽ (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy [Completed]
The purpose of this study is to establish the objective response rate (complete response +
partial response), following treatment with Alimta plus VELCADE, Alimta alone, or VELCADE
alone in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who
have failed prior preventative therapy for Stage IIIb/IV NSCLC. The Alimta alone treatment
group will be used as the control. The VELCADE single-agent treatment group will be used to
determine if VELCADE administered weekly can demonstrate response rates.
ZD6474(Vandetanib) + Alimta Combo Study [Active, not recruiting]
The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets)
to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help
control their symptoms and disease better than the chemotherapy alone.
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. [Completed]
Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA
for the treatment of cancer of the pancreas. Patients may be able to participate in this
study if they have cancer in their pancreas that cannot be removed by surgery OR that has
spread to a new site in their body.
Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer [Completed]
To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed
for the treatment of patients with locally advanced or metastatic NSCLC who have failed one
prior chemotherapy regimen
Reports of Suspected Alimta (Pemetrexed) Side Effects
Neoplasm Progression (81),
Interstitial Lung Disease (47),
Pyrexia (33), more >>
Page last updated: 2014-12-11